Ono, BMS Agree To Joint Development, Marketing Of Cancer Drugs
This article was originally published in PharmAsia News
Executive Summary
Ono Pharmaceutical and Bristol-Myers Squibb have agreed to 50-50 joint development and marketing several immunotherapies of the Japan-based company.